Custom
Request 

Research Report Details

Author / Researcher : Global Markets Direct

Report Statistics

Number Of Pages/Tabs : 72

Number Of Charts : N/A

Published Date : 04/27/2016

Industries : Multiple

Countries : All

Quality Score : 5

Have a question about this report?
24/7 Research Support
Talk to Zursh Analyst
+1 858 522 9998 or Email Us

Narcolepsy - Pipeline Review, H1 2016
Narcolepsy - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Narcolepsy - Pipeline Review, H1 2016’, provides an overview of the Narcolepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Narcolepsy - The report reviews pipeline therapeutics for Narcolepsy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Narcolepsy therapeutics and enlists all their major and minor projects - The report assesses Narcolepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Narcolepsy Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Narcolepsy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

;
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Narcolepsy Overview 8
Therapeutics Development 9
Pipeline Products for Narcolepsy - Overview 9
Pipeline Products for Narcolepsy - Comparative Analysis 10
Narcolepsy - Therapeutics under Development by Companies 11
Narcolepsy - Therapeutics under Investigation by Universities/Institutes 12
Narcolepsy - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Narcolepsy - Products under Development by Companies 16
Narcolepsy - Products under Investigation by Universities/Institutes 17
Narcolepsy - Companies Involved in Therapeutics Development 18
Bioprojet SCR 18
Evotec AG 19
Flamel Technologies S.A. 20
H.A.C. Pharma 21
Jazz Pharmaceuticals Plc 22
NLS Pharma Group 23
Sanofi 24
SK Biopharmaceuticals Co., Ltd. 25
Taisho Pharmaceutical Holdings Co., Ltd. 26
Theranexus SAS 27
Narcolepsy - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 35
Drug Profiles 36
(modafinil + THN-02) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
arbaclofen - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
JZP-386 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
mazindol - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
mazindol - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NLS-3 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Pentylenetetrazol - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pitolisant - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SAR-110068 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SKL-N05 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Agonize Orexin Receptor 2 for Nacrcolepsy - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Agonize Orexin Receptor for EDS and Narcolepsy - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
sodium oxybate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
sodium oxybate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
TS-091 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Narcolepsy - Recent Pipeline Updates 57
Narcolepsy - Dormant Projects 62
Narcolepsy - Discontinued Products 63
Narcolepsy - Product Development Milestones 64
Featured News & Press Releases 64
Mar 31, 2016: Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate 64
Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep 64
Nov 20, 2015: Narcolepsy treatment recommended for approval 65
Jul 15, 2015: Theranexus Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies 65
Jun 04, 2015: Jazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem(sodium oxybate) at SLEEP 2015 66
May 07, 2015: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 67
Dec 19, 2014: Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump Sodium Oxybate 67
Dec 09, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 68
Dec 02, 2014: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy 69
Jul 21, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386 69
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72

List of Tables
Number of Products under Development for Narcolepsy, H1 2016 9
Number of Products under Development for Narcolepsy - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Narcolepsy - Pipeline by Bioprojet SCR, H1 2016 18
Narcolepsy - Pipeline by Evotec AG, H1 2016 19
Narcolepsy - Pipeline by Flamel Technologies S.A., H1 2016 20
Narcolepsy - Pipeline by H.A.C. Pharma, H1 2016 21
Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H1 2016 22
Narcolepsy - Pipeline by NLS Pharma Group, H1 2016 23
Narcolepsy - Pipeline by Sanofi, H1 2016 24
Narcolepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 25
Narcolepsy - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 26
Narcolepsy - Pipeline by Theranexus SAS, H1 2016 27
Assessment by Monotherapy Products, H1 2016 28
Assessment by Combination Products, H1 2016 29
Number of Products by Stage and Target, H1 2016 31
Number of Products by Stage and Mechanism of Action, H1 2016 33
Number of Products by Stage and Route of Administration, H1 2016 34
Number of Products by Stage and Molecule Type, H1 2016 35
Narcolepsy Therapeutics - Recent Pipeline Updates, H1 2016 57
Narcolepsy - Dormant Projects, H1 2016 62
Narcolepsy - Discontinued Products, H1 2016 63

List of Figures
Number of Products under Development for Narcolepsy, H1 2016 9
Number of Products under Development for Narcolepsy - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 28
Number of Products by Targets, H1 2016 30
Number of Products by Stage and Targets, H1 2016 30
Number of Products by Mechanism of Actions, H1 2016 32
Number of Products by Stage and Mechanism of Actions, H1 2016 32
Number of Products by Stage and Routes of Administration, H1 2016 34
Number of Products by Stage and Molecule Types, H1 2016 35

Summary of Source & Methodology

True

Global Markets Direct follows the highest standards when conducting primary and secondary research, including thousands of interviews with senior executives every year, to enable clients to make sound business decisions for their company in complete confidence. 1. 1 million-strong stakeholder group, plus 25,000 interviews annually 2. Rigorous checks on over 25,000 public and proprietary sources 3. Data modeled and forecasted with gold-standard methodology 4. Updated in real time 5. Expert insights and critical analysis from 700 experienced researchers and analysts If you would like to request the complete research methodology of this report or any additional information, please send us an email to reports@zursh.com

Download additional documents & original sources used by researcher/publisher to support the report data

Download Documents
No documents available for download

Zursh quality control analysts have developed a nice rating algorithm to independently and objectively evaluate the quality of this report.

Quality Score : 5
Content 5
Reputation 5
Sources 5
Presentation 5
Global Markets Direct is a leading provider of global business intelligence and market analysis. The company publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. At the heart of Global Markets Direct are unique databases, updated live, covering millions of rows of key information for the studied industry at a global level.